The world’s first device that facilitates intubation procedure while protects patient and clinicians
100 million intubations every year. A 45% complication rate in critically ill patients. $5.94 billion of annual cost of peri-intubation morbidity and complications in the U.S.
See the evidence
€8M
Pre-money valuation
x8
Estimated return multiple
9%
Equity offered
€1,000
Minimum investment
2030
Estimated exit via acquisition by major medtech player
VALIDATED BY:
CE Mark · EU
FDA ‘Safer Designation’ · USA
ANVISA · Brazil
TITCK · Turkey
Global PCT Patent · 20 Years
2 Prior Capital Cell Rounds Completed
4 Preclinical studies and 2 Clinical Trials
— THE PROBLEM
A procedure performed 100 million times a year
Endotracheal intubation is the third most performed medical procedure in hospitals worldwide. Despite decades of technological progress, this procedure is performed in exactly the same way as 70 years ago.
+100M
intubations per year worldwide — across ERs, ICUs, operating theatres, and pre-hospital emergencies.
45%
of intubations in critically ill patients end in serious complications — hypoxia, cardiac arrest, haemodynamic instability, and death.
30%
of all anaesthesia-related medico-legal complaints are caused by dental and oral trauma during intubation.
10%
of healthcare workers involved in the intubation of patients diagnosed with COVID-19 later developed symptoms of the infection.
“Despite decades of important technological advances in airway management, including videolaryngoscopes, no device has reliably solved the dual challenge of guiding the tube and protecting patients and staff simultaneously during endotracheal intubation. The Airway Shield™ makes this procedure, even in critical settings, easier, faster and safer, helping to save lives.”
Dr. Julio Alonso — Founder & CEO, AIRWAY SHIELD SLIntensive Care Specialist
— THE DEVICE
Making Endotracheal Intubation easier, faster and safer for both patients and clinicians
Airway Shield™, ready for commercialization, is a patented, single-use barrier mouthpiece that combines critical advantages in a single device. Airway Shield™ combines faster, safer, and simpler intubation, giving it a radical competitive advantage and positioning it to become the new standard of care worldwide.
Guided intubation
A reinforced guiding channel directs the endotracheal tube precisely toward the trachea, enabling faster and more accurate placement of the tube and reducing the risk of esophageal intubation.
50% reduction in intubation time and 100% first pass success in preclinical studies 1,2
Patient Protection
The device is a barrier mouthpiece that protects teeth and oral mucosa – the main source of complaints in anaesthesia worldwide.
70% reduction in the force applied over the incisors demonstrated in a preclinical study 2
Clinician Protection
A shield covers the patient´s mouth and minimizes the spread of aerosols and droplets during the procedure.
95% reduction in aerosols and droplets exposure during endotracheal intubation demonstrated in a preclinical study 3
Institutional & Insurer Value
Airway ShieldTM facilitates the procedure, reduces complications and protects patients, supporting safe intubation in over 100 million procedures annually.
The annual national cost of peri-intubation complications just in US, is estimated to be $ 5.94billion 4
1. Alonso, JM. et al. (2021). [Poster]. European Society of Intensive Care Medicine (ESICM).
2. Alonso, JM. et al. (2025). [Poster]. World Airway Management Meeting (WAMM), Florencia, Italia.
3. Alonso, JM. et al. (2022). Eur J Anaesthesiol. doi:10.1097/EJA.0000000000001731
4. Amber L. Schilling, Christopher S. Hollenbeak et al. (2019). Estimating the Economic and Absolute Number of Complications Associated with Emergency Intubations Performed Outside the Operating Room. Pennsylvania State University College of Medicine.
Regulatory & IP
Patent Cooperation Treaty (PCT)
Q2 – 2020
CE Mark
Q1 – 2022
FDA ‘Safer Technology’
Q3 – 2022
ANVISA (Brazil)
Q4 – 2023
Japanese Patent Granted
Q2 – 2024
TITCK (Turkey)
Q4 – 2024
U.S. Patent Granted
Q3 – 2025
Chinese Patent Granted
Q1 – 2026
Hong Kong subsidiary established
Q1 – 2026
Europe Patent
Q2 – 2026
FDA clearance
Q2/Q3 – 2026
U.S. subsidiary
Q3 – 2026
Clinical Validation
1st Preclinical Study Completed
Q4 – 2021
2nd Preclinical Study Completed
Q2 – 2022
1st Preclinical Study Publication
Q2 – 2023
1st Clinical Study Completed
Q1 – 2024
2nd Clinical Study Completed
Q3 – 2024
3rd Preclinical Study Completed
Q1 – 2025
4th Preclinical Study Completed
Q2 – 2025
Multicenter Study Kick-off
Q4 – 2026
1st Study in UCI
Q1 – 2027
Manufacturing & Distribution
1st Manufacturing Agreement
Q3 – 2020
2nd Manufacturing Agreement
Q3 – 2024
Brazilian Distribution Agreement
Q2 – 2024
Turkish Distribution Agreement
Q4 – 2024
Production Capacity
Q3 – 2025
First sales
Q1 – 2026
New developments (pediatrics sizes & video-AWS)
Q2 – 2027
Europe Manufacturing Agreement
Q1 – 2027
U.S. Manufacturing Agreement
Q2 – 2027
— USE OF INVESTMENT
What we do with your capital
This Round III raise of €800,000 is the commercial inflection point — taking Airway Shield™ from a CE-marked, clinically validated device to a fully commercial, US-ready medical device business with the international reach that triggers acquisition interest.
60%
Market Expansion
Accelerate commercial expansion in Spain and Europe by strengthening our sales team, activating key distributor partnerships, and supporting targeted marketing and promotional initiatives to drive adoption.
Launch our U.S. expansion strategy by leveraging our FDA clearance to establish a local presence, build market access capabilities, and prepare for commercial rollout.
≈ €480,000
30%
Clinical Validation
Generate additional clinical and scientific evidence through international clinical trials, peer-reviewed publications, and real-world studies to drive clinician adoption, strengthen KOL advocacy, and accelerate future product developments, including paediatric sizes and Video-AWS™.
≈ €240,000
10%
Scale-up Readiness
Scale-up Readiness
Strengthen quality management systems, regulatory compliance and maintenance, and intellectual property protection to support the scalable deployment of Airway Shield across regulated international markets.
≈ €80,000
TOTAL RAISE: €800,000 · MINIMUM INVESTMENT: €1,000 · EQUITY OFFERED: 9%
€800K
— MARKET OPPORTUNITY
A $2.6 billion market.
One unsolved problem.
Endotracheal intubation is the third most common medical procedure worldwide and remains one of the most critical high-risk procedures in hospital care. Airway ShieldTM targets an unmeet need of this market with a patented solution designed to make intubation safer, faster and more controlled.
Unlike conventional airway devices, Airway ShieldTM combines three key advantages in a single device: effective endotracheal tube guidance, patient protection against dental and mucosal trauma, and clinician protection from aerosol exposure.
With global patent protection covering more than 90% of the international market, CE marking in Europe, FDA Safer Technology designation, and a FDA clearance decision expected shortly, together with a robust clinical validation Airway Shield is positioned to become a new standard in safer intubation.
100M
intubations performed globally every year — across ERs, ICUs, ORs, and pre-hospital settings
$2.6B
global airway management devices market, growing to $3.8B+ by 2033 at ~5.6% CAGR
$5.4B
of annual national cost of peri-intubation morbidity and complications in the U.S, due to prolonged hospital stays, additional treatments and legal claims
x8
estimated return multiple, with exit targeted for 2030 via strategic acquisition
— EXIT PRECEDENTS
Major players acquire exactly this category.
Airway Shield’s exit strategy — acquisition by a major medtech player — follows a clear, documented pattern.
ACQUISITION PRECEDENT #1 · 2012
Teleflex acquires LMA International
$276M
Teleflex — a leading global critical care device company — acquired LMA International, the world’s foremost maker of laryngeal mask airway devices used in anaesthesia and emergency care. LMA had revenues of ~$124M at acquisition. The deal was immediately accretive and gave Teleflex a dominant market position in airway management.
↗ Why it matters: LMA operated in the same clinical environment — anaesthesia and emergency airway management. Teleflex paid a premium multiple for unique device IP in a high-frequency procedure.
ACQUISITION PRECEDENT #2 · 2023
Inogen acquires Physio-Assist (Simeox)
Up to $45M
Inogen, a NASDAQ-listed global respiratory company, acquired Physio-Assist — a CE-marked French medtech startup with early European commercial presence — for up to $45M. The Simeox device addressed airway clearance. Inogen bought before FDA clearance, betting on the regulatory pathway and clinical differentiation.
↗ Why it matters: This is the same acquisition profile as AirwayShield today — CE-marked European startup, differentiated device, proven early commercial traction, clear FDA pathway. Inogen acquired precisely at the stage AirwayShield is now reaching.
The pattern is consistent across the industry: Medtronic, Teleflex, ICU Medical, Ambu, and their peers systematically acquire CE-marked, IP-protected device companies with proven clinical differentiation and a clear US pathway — rather than develop competing products internally. AirwayShield is built to that specification.
— INVESTMENT TERMS
Round III
The commercial milestone
PRE-MONEY VALUATION
€8M
EQUITY OFFERED
9%
Full shareholder rights · Drag-along & tag-along
ESTIMATED EXIT YEARS
2030
Acquisition by strategic buyer · x8 return potential estimated
MINIMUM INVESTMENT
€1,000
Join the investors making safer intubation a reality
Invest via Capital Cell
— WHY ROUND III IS DIFFERENT
Two rounds completed.
Now we scale.
Airway Shield SL, with its device ready for commercialization and the first sales achieved, open its third Funding Round to scale the project internationally, acquiring significant market share in Europe, entering the US market and continuing building clinical evidence.
ROUND I · €400K · COMPLETED
Proof of Concept
Established the team. Lead Investors group from Santander (Spain). Funding Round completed in 24 hours through Crowdfunding via Capital Cell Platform.
ROUND II · €680K · COMPLETED
Clinical Evidence & Automatic Molding
Following CE marking approval, the purpose of the round was to raise funds to generate clinical and scientific evidence and to design an automated dual-cavity mould to ensure scalable and reliable manufacturing capacity. Lead Investors group from ESADE (Spain). Funding Round completed in 10 days through Crowdfunding via Capital Cell Platform.
ROUND III · OPEN NOW
Commercial Scale & US Market Entry
With CE mark in hand, peer-reviewed publications confirmed, and European distribution underway, this round is the commercial inflection point. Capital is deployed into market expansion, FDA submission, additional clinical evidence, and the innovation pipeline — building the acquisition profile that major players will act on by 2030. This is the round that sets the exit in motion.
— INVESTOR QUESTIONS
What investors
ask us most.
Is this investment available to non-specialist individual investors?
Yes. We have a Lead Investor Group that has committed a total of €210K before the campaign is open via Capital Cell. No medical or technical background is required. Capital Cell is authorised by Spain’s CNMV (licence PFP nº12) and regulated under EU ECSP rules. Register on Capital Cell to access the full investor dossier, financial projections, and due diligence documentation.
What is the planned exit and how is the x8 return estimated?
The planned exit is acquisition by a major medical device company (such as Medtronic, Teleflex, ICU Medical, or Ambu) around 2030. Capital Cell’s x8 estimate is based on comparable airway management device transactions, the €8M pre-money valuation, and projected revenues by exit year. As with all early-stage investment, returns are not guaranteed and capital is at risk.
What are my rights as a shareholder?
Investors receive equity with standard protections: anti-dilution rights, drag-along and tag-along rights, liquidation preference, and quarterly shareholder reporting. Capital Cell represents investor interests at Airway Shield’s shareholder meetings.
Why a third Capital Cell round rather than a VC raise?
Airway ShieldTM has chosen Capital Cell strategically — it builds a community of aligned investors (clinicians, medtech professionals, patients, healthcare advocates) who become brand advocates, not just shareholders. Two prior rounds have been completed successfully, proving the model works. This round is the largest and most commercially significant.
— ROUND III · AIRWAY SHIELD · OPEN NOW —
Invest to achieve a safer intubation everywhere
100 million of intubations performed every year. A medical device born from real clinical experience.
Be part of the future standard of care in endotracheal intubation!